FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947875830> ?p ?o ?g. }

• W2947875830 endingPage "175883591985397" @default.
• W2947875830 startingPage "175883591985397" @default.
• W2947875830 abstract "Preclinical evidence suggests that zoledronic acid (ZOL) works synergistically with chemotherapy by enhancing anti-tumor activity. ZOL blocks the mevalonate pathway and may indirectly interact with human epidermal growth factor receptor 2 (HER2) pathway activation. The clinical efficacy and biological rationale of chemotherapy plus anti-HER2 therapy and ZOL as a part of neoadjuvant therapy has not been previously tested.We conducted a phase II clinical trial to evaluate the efficacy and safety of ZOL as part of a neoadjuvant treatment in patients with HER2-positive breast cancer (BC). The protocol consisted of four cycles of doxorubicin/cyclophosphamide with ZOL, followed by four cycles of docetaxel with trastuzumab and ZOL prior to surgery. The primary endpoint was the pathologic complete response (pCR) rate. Secondary endpoints were safety and the identification of clinicopathological characteristics associated with pCR.A total of 71 patients with stage IIA to IIIB BC were included, with 60 eligible for the safety assessment and 58 for the efficacy analysis. Overall, the pCR rate was 42%, with higher rates in hormone receptor (HR)-positive tumors (40%), which contrasts with the results of pivotal trials. The most commonly observed grade 3 and 4 events were febrile neutropenia (grade 3, 20%; grade 4, 3%) and diarrhea (grade 3, 12%).The addition of ZOL as a repositioning drug in neoadjuvant treatment was an effective and well-tolerated therapy. This drug combination might overcome endocrine and anti-HER2 resistance. The higher pCR rates in the HR-positive subgroup deserve further translational investigation." @default.
• W2947875830 created "2019-06-07" @default.
• W2947875830 creator A5009475477 @default.
• W2947875830 creator A5009680452 @default.
• W2947875830 creator A5010594518 @default.
• W2947875830 creator A5018142979 @default.
• W2947875830 creator A5018237592 @default.
• W2947875830 creator A5033292523 @default.
• W2947875830 creator A5041119043 @default.
• W2947875830 creator A5053559172 @default.
• W2947875830 creator A5056263148 @default.
• W2947875830 creator A5062819390 @default.
• W2947875830 creator A5068804744 @default.
• W2947875830 creator A5075774024 @default.
• W2947875830 creator A5078204331 @default.
• W2947875830 creator A5085015178 @default.
• W2947875830 date "2019-01-01" @default.
• W2947875830 modified "2023-10-14" @default.
• W2947875830 title "Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial" @default.
• W2947875830 cites W1635038849 @default.
• W2947875830 cites W1771499318 @default.
• W2947875830 cites W1987326983 @default.
• W2947875830 cites W1997381761 @default.
• W2947875830 cites W2011826559 @default.
• W2947875830 cites W2014647709 @default.
• W2947875830 cites W2015512041 @default.
• W2947875830 cites W2037559407 @default.
• W2947875830 cites W2056579307 @default.
• W2947875830 cites W2077073060 @default.
• W2947875830 cites W2087800175 @default.
• W2947875830 cites W2095698687 @default.
• W2947875830 cites W2095861620 @default.
• W2947875830 cites W2095865154 @default.
• W2947875830 cites W2101979288 @default.
• W2947875830 cites W2114195503 @default.
• W2947875830 cites W2123591186 @default.
• W2947875830 cites W2125885282 @default.
• W2947875830 cites W2127286421 @default.
• W2947875830 cites W2138691465 @default.
• W2947875830 cites W2147415463 @default.
• W2947875830 cites W2155560234 @default.
• W2947875830 cites W2162982444 @default.
• W2947875830 cites W2163949875 @default.
• W2947875830 cites W2165003903 @default.
• W2947875830 cites W2198494082 @default.
• W2947875830 cites W2283816551 @default.
• W2947875830 cites W2337408646 @default.
• W2947875830 cites W2546045828 @default.
• W2947875830 cites W2590129626 @default.
• W2947875830 doi "https://doi.org/10.1177/1758835919853971" @default.
• W2947875830 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6545654" @default.
• W2947875830 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31210800" @default.
• W2947875830 hasPublicationYear "2019" @default.
• W2947875830 type Work @default.
• W2947875830 sameAs 2947875830 @default.
• W2947875830 citedByCount "5" @default.
• W2947875830 countsByYear W29478758302019 @default.
• W2947875830 countsByYear W29478758302021 @default.
• W2947875830 countsByYear W29478758302022 @default.
• W2947875830 crossrefType "journal-article" @default.
• W2947875830 hasAuthorship W2947875830A5009475477 @default.
• W2947875830 hasAuthorship W2947875830A5009680452 @default.
• W2947875830 hasAuthorship W2947875830A5010594518 @default.
• W2947875830 hasAuthorship W2947875830A5018142979 @default.
• W2947875830 hasAuthorship W2947875830A5018237592 @default.
• W2947875830 hasAuthorship W2947875830A5033292523 @default.
• W2947875830 hasAuthorship W2947875830A5041119043 @default.
• W2947875830 hasAuthorship W2947875830A5053559172 @default.
• W2947875830 hasAuthorship W2947875830A5056263148 @default.
• W2947875830 hasAuthorship W2947875830A5062819390 @default.
• W2947875830 hasAuthorship W2947875830A5068804744 @default.
• W2947875830 hasAuthorship W2947875830A5075774024 @default.
• W2947875830 hasAuthorship W2947875830A5078204331 @default.
• W2947875830 hasAuthorship W2947875830A5085015178 @default.
• W2947875830 hasBestOaLocation W29478758301 @default.
• W2947875830 hasConcept C121608353 @default.
• W2947875830 hasConcept C126322002 @default.
• W2947875830 hasConcept C143998085 @default.
• W2947875830 hasConcept C203092338 @default.
• W2947875830 hasConcept C2776326535 @default.
• W2947875830 hasConcept C2776694085 @default.
• W2947875830 hasConcept C2776755627 @default.
• W2947875830 hasConcept C2778292576 @default.
• W2947875830 hasConcept C2779786085 @default.
• W2947875830 hasConcept C2781190966 @default.
• W2947875830 hasConcept C530470458 @default.
• W2947875830 hasConcept C535046627 @default.
• W2947875830 hasConcept C71924100 @default.
• W2947875830 hasConceptScore W2947875830C121608353 @default.
• W2947875830 hasConceptScore W2947875830C126322002 @default.
• W2947875830 hasConceptScore W2947875830C143998085 @default.
• W2947875830 hasConceptScore W2947875830C203092338 @default.
• W2947875830 hasConceptScore W2947875830C2776326535 @default.
• W2947875830 hasConceptScore W2947875830C2776694085 @default.
• W2947875830 hasConceptScore W2947875830C2776755627 @default.
• W2947875830 hasConceptScore W2947875830C2778292576 @default.
• W2947875830 hasConceptScore W2947875830C2779786085 @default.
• W2947875830 hasConceptScore W2947875830C2781190966 @default.

• next